Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 17, 2021 (5 years ago)

Morphine Sulfate Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective container: Cracked vials leading to lack of sterility assurance

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Morphine Sulfate Injection, USP, 2 mg per mL, 1 mL single dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-452-01. 25 vials per tray packaged 18 trays per shipper

Affected NDC 63323-0452-01

Compare with the code on your package — it is the most precise check available.

Drug: Morphine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Morphine Sulfate
NDC 63323-0452
2 mg/mL Injection, Solution
Intramuscular|intravenous
Fresenius Kabi USA, LLC Rx · CII
Recalling firm
Fresenius Kabi USA LLC
NDC code
63323-452-01
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0856-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Morphine recalls

See all
Class I · High risk

Morphine Sulfate Injection

Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.

Ongoing Labeling / mix-up Fresenius Kabi USA, LLC D-0788-2026

Other recalls by Fresenius Kabi USA LLC

All 2021 recalls
Class I · High risk

Tyenne (tocilizumab-aazg)

Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.

Ongoing Particulate / foreign matter Fresenius Kabi USA, LLC NDC 65219-594-20 D-0827-2026
Class I · High risk

Morphine Sulfate Injection

Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.

Ongoing Labeling / mix-up Fresenius Kabi USA, LLC D-0788-2026